Jeffrey S. Hatfield

Director

Jeffrey S. Hatfield has served as a member of our Board since December 2020. 

Mr. Hatfield currently serves as Chairman of the Board for both Vividion Therapeutics, Inc., a chemoproteomics pioneer within the Pharmaceutical division of Bayer AG, and ROME Therapeutics, a biotech leading exploration of the dark genome, as well as on the board of directors of Gate Bioscience, Inc., a preclinical biotech creating a new class of medicines that aim to cure diseases by selectively eliminating harmful proteins that originate inside the cell.

Mr. Hatfield has more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. 

Among his many biotech leadership roles, Mr. Hatfield previously served as CEO of Vividion Therapeutics, Inc., from 2020 through its arm’s length subsidiary model acquisition by Bayer, and until his retirement in Jan 2023, as CEO and a board member of Zafgen, Inc., a publicly traded biopharmaceutical company, from 2017 until its acquisition of (and name change to) Larimar Therapeutics, Inc. in 2020, and as CEO and a board member of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he worked from start-up in 2004 until the company’s acquisition by Allergan plc in 2016. 

Prior to his biotech career, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held various roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. 

Mr. Hatfield currently serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. 

Mr. Hatfield holds a B.S. from the Purdue University College of Pharmacy and an MBA from The Wharton School, University of Pennsylvania.